Hemispherx Biopharma Inc., of Philadelphia, presented a summary of the results of its Phase I/II study at the American Society for Microbiology Biodefense Conference in Washington, showing that when Flumist, a seasonal influenza vaccine, was administered intranasally in conjunction with the company’s Ampligen, a Toll-like receptor 3 agonist, 92 percent of subjects elaborated specific IgA antibodies against at least one of the homologous seasonal vaccine strains.